Grifols SA (GRFS) shares rallied sharply during the intraday trading session on Wednesday, soaring 6.37% on the back of robust fourth-quarter financial results. The Spanish pharmaceutical and healthcare company reported impressive growth in its key metrics for the quarter.
The company's revenue for the quarter climbed 13.6% year-over-year on a constant currency basis, reaching €1.976 billion. A significant contributor to this growth was the strong performance of Grifols' Bioscience division, which saw increased demand for its plasma-derived therapies.
Grifols also reported a 19% year-over-year increase in its adjusted EBITDA, which stood at €526 million for the fourth quarter. This impressive growth in profitability can be attributed to the company's operational efficiency and cost control measures, as well as the robust top-line performance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。